Slides
Page 2
SAFE HARBOR DISCLAIMER •This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this presentation regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among other things, statements about (i) our ability to identify and penetrate new markets for our products and technology; (ii) our ability to innovate, develop and commercialize our existing and new products; (iii) our ability to obtain and maintain regulatory clearances; (iv) our expectation regarding the safety and efficacy of our products; (v) commercial experience of our management team; (vi) our commercialization, marketing and manufacturing capabilities and strategy; (vii) our estimates regarding the potential market opportunity for our products; (viii) developments and projections relating to our competitors or our industry; (ix) our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; (x) our sales and marketing capabilities and strategy in the United States and internationally; (xi) the implementation of our business model, strategic plans for our business, products and technology; (xii) our ability to attract or retain key employees and advisors; (xiii) our intellectual property portfolio and position; and (xiv) our estimates regarding expenses, future revenues, capital requirements and needs for additional financing. •We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward- looking statements. Forward-looking statements are based on our management’s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and our management’s beliefs and assumptions, and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. •Forward-looking statements are subject to numerous risks and uncertainties, including, among other things, those resulting from the pandemic caused by the ongoing global COVID-19 pandemic and those described under “Risk Factors” in our Annual Report on Form 20-F for the year ended December 31, 2019 as filed with the Securities and Exchange Commission (“SEC”). Other risks, uncertainties and factors that could cause actual results to differ materially from the forward-looking statements included in this presentation may be described from time to time in reports we file with the SEC. The forward-looking statements contained in this presentation are made as of the date of this presentation, and we do not assume any obligation to update any forward-looking statements except as required by applicable law.
Page 3
COMPANY OVERVIEW OVERVIEW
Page 4
INMODE: WHO WE ARE Leading global provider of innovative, minimally-invasive aesthetic and wellness solutions, with strong brand recognition Broad radiofrequency (“RF”) based portfolio (capital and consumables) providing specialized aesthetic and wellness solutions to plastic surgeons, dermatologists, OB/GYNs, ENTs and ophthalmologists Worldwide regulatory approvals supported by extensive peer-reviewed published clinical data Demonstrated history of profitable growth Global platform with an established direct sales force and extensive distributor network Pipeline to expand medical offerings and adapt proprietary RF technologies to specific applications for plastic and aesthetic surgeons, OB/GYNs, ENTs and ophthalmologists Proven management team with extensive business, scientific and technology experience and expertise 1 2 3 4 5 6 7
Page 5
13,100 US Installed Base 30,980 Unit Installed Worldwide $29.4M Q4-2025 Non-GAAP Net Income INMODE Q4 2025: BY THE NUMBERS 79% Q4-2025 Non-GAAP Gross Margin $0.46 Q4-2025 Non-GAAP Diluted Earning per Share 285 Direct Sales Reps $103.9M Q4-2025 Revenue 22 Patented Technologies Across 12 Product Families Selling in 101 Countries
Page 6
13,100 US Installed Base 30,980 Unit Installed Worldwide $105.5M FY-2025 Non-GAAP Net Income INMODE FY 2025: BY THE NUMBERS 79% FY-2025 Non-GAAP Gross Margin $1.60 FY-2025 Non-GAAP Diluted Earning per Share 285 Direct Sales Reps $370.5M FY-2025 Revenue 22 Patented Technologies Across 12 Product Families Selling in 101 Countries
Page 7
•20 + years industry experience •Co-Founder; CEO of InMode since its inception in 2008 •Co-Founder and former CEO of Syneron •BS in Engineering from Tel Aviv University; MBA from Pace University •20 + years industry experience •Co-Founder; CTO of InMode since its inception in 2008 •Co-Founder and former CTO of Syneron; inventor of ELOS technology •PhD in Nuclear Physics; recognized as pioneer of RF and IPL technologies •15 + years industry experience •CFO of InMode since 2017 •Former Director of Finance for Jazz Semiconductor and Controller of Syneron •BA in Accounting / Economics from Haifa University; MBA from Tel-Aviv University THE INMODE EXECUTIVE TEAM •A decade of leadership experience with InMode, holding roles from District Sales Manager to President •Proven track record of building sales organizations and driving revenue growth across multiple regions •Business Degree from Lake Erie College in Cleveland MOSHE MIZRAHY Co-Founder & Chief Executive Officer YAIR MALCA Chief Financial Officer DR. MICHAEL KREINDEL, Ph.D Co-Founder & Chief Technology Officer MICHAEL DENNISON President, North America
Page 8
INMODE GLOBAL ORGANIZATION SELLING IN 101 COUNTRIES 660 employees worldwide, including 285 direct sales reps and 40 person R&D team •186 persons direct sales force in the US and Canada •Logistics Centers in L.A. and Toronto •Exclusive distributors by country in South America •Sales and marketing office in Buenos Aires, Argentina •In the process of establishing a subsidiary in Argentina •Wholly-owned subsidiaries in Spain, France, UK, Italy and Germany •Exclusive distributors by country •Middle East countries via UK •Corporate headquarters •R&D and engineering center •Manufacturing and logistics •Corporate finance •Wholly-owned subsidiary in Israel •Exclusive distributors in Israel •Wholly-owned subsidiaries in Australia, India, China Japan and Thailand •Exclusive distributors by country •Sales and marketing office in Japan ISRAEL EUROPE AMERICAS ASIA
Page 9
THE EVOLVING AESTHETICS MARKET
Page 10
THE UNMET NEED IN MEDICAL AESTHETICS: THE “TREATMENT GAP” ✓40 million procedures annually worldwide ✓Non-invasive, in-office, topical procedures ✓Typical treatments: hair removal, pigmented lesions, vascular lesions, leg veins, acne ✓Multiple treatments and limited efficacy ✓Demographics: 35-60 yrs. old ✓Looking for comparable results to plastic surgery, but without the shortcomings of full surgery including: ▪Anesthesia, downtime, scars ✓Large population of patients whose skin is not responsive to other skin tightening modalities ✓Affordable, office-based, out-patient procedure ✓2.5 million procedures annually worldwide ✓Full surgical procedure, with general anesthesia ✓Lengthy downtime ✓High cost ✓Incisions and scars ✓Low repeatability, dependent on the doctor’s technique PLASTIC SURGERYTHE “TREATMENT GAP”LASER PROCEDURES Significant opportunity for innovative and differentiated minimally-invasive solutions Significant opportunity for InMode to invent and develop minimally-invasive technologies and products for the “Treatment Gap” category ________________________ Source: Medical Insights (2017), ASAPS (2018).
Page 11
SOLUTION FOR THE TREATMENT GAP – EVOLUTIONARY PROGRESS Traditional laser companies INMODE
Page 12
AESTHETICS INDUSTRY UNDERGOING A PARADIGM SHIFT To: Minimally-Invasive/Ablative Aesthetic Surgery From: Traditional Laser-Based Aesthetics •In-office procedures – mainly hair removal •Non-invasive laser-based procedures •Very limited results that typically require multiple treatments •Patients are seeking new procedures with more significant and longer-lasting results •Growing demand for face and body procedures and not just “laser” rejuvenation or hair removal The new competitive dynamics of the aesthetic surgery industry require a major technological change and a new product portfolio “Treatment Gap” patients are increasingly looking for solutions that address the shortcomings of laser-based aesthetics and the complexity of full surgery
Page 13
WHO DO WE SERVE? Significant U.S. Market Opportunity GYN Ophthal- mologists Plaspc / Derm / Aesthepcs ENT (# of Surgically-Trained Physicians) InMode’s Major Customers In response to physicians’ desires to expand their offering of our aesthetic and wellness office-based procedures, we are developing additional RF solutions targeting their specialties ________________________ Source: Medical Insights (2017), ASAPS (2018) Source: Doctors’ Associations. Note: Estimates based on 2018 data. •100,000+ surgically-trained physicians in the U.S. and 200,000+ globally •While not all of these physicians focus on aesthetics, many do perform aesthetic procedures •Interested in adding specific medical / wellness procedures related to their area of expertise •“Private pay procedures augment physicians” income – office-based procedures
Page 14
REFINED TECHNOLOGY • ENHANCED PRECISION • EXCEPTIONAL RESULTS INMODE SOLUTIONS PROPRIETARY TECHNOLOGIES
Page 15
RFAL Technology Soft Tissue Contraction for the face and body results without the large visible scars – the “Holy Grail of Plastic Surgery” ✓Delivers directional RF energy into the subcutaneous fat. ✓Allows the treatment of larger volumes of the subcutaneous tissue. ✓Clinical studies demonstrate change of the skin is significant and can reach up to 40% of the heated tissue volume. ✓BodyTite Turbo and FaceTite Turbo - enhanced RFAL handpieces engineered for more power, more precision, and faster results. RFAL - RADIOFREQUENCY ASSISTED LIPO-COAGULATION InMode Proprietary Technology I
Page 16
BEFORE & AFTER: BODY PROCEDURES USING RFAL ___________________________ Note: These are sample results and may not be indicative of actual results. “After” results reflect 1 treatment.
Page 17
✓Advanced technology discharging fractionated radiofrequency (FRF) internally to maximal depths. ✓FDA cleared for soft tissue contraction. ✓Delivers bipolar pulsed RF to new maximal depths of up to 60mm, without damaging the dermis. ✓QuantumRF 25 for body and QuantumRF 10 for smaller zones. ✓Results in shorter downtimes and safer procedures. InMode Proprietary Technology II
Page 18
QUANTUMRF 10 Six weeks after a single QuantumRF treatment showing quick recovery and minimal downtime. ___________________________ Note: These are sample results and may not be indicative of actual results.
Page 19
SUBDERMAL FRACTIONAL RF (FRF) Deep Subdermal Fractional RF (FRF) High-quality results with fewer treatments and shorter downtimes than full aesthetic solutions ✓Delivers bipolar RF energy under the dermis through an array of needle electrodes producing localized heat and small pinpoint coagulation ✓Heat generated by pins in the sub-dermal tissue promotes even treatment results in targeted sessions ✓Popular treatment in young and older patients InMode Proprietary Technology III
Page 20
Soft tissue coagulation Tissue contraction Hemostasis Penetration depth up to 7mm NEW FDA INDICATIONS
Page 21
MORPHEUS8 GLOBAL AWARENESS & ADOPTION
Page 22
FACE TREATMENT SUBDERMAL FRACTIONAL RF ___________________________ Note: These are sample results and may not be indicative of actual results. “After” results reflect 3 treatments 6 weeks apart
Page 23
BODY USING DEEP SUBDERMAL FRACTIONAL RF ___________________________ Note: These are sample results and may not be indicative of actual results. “After” results reflect 2 treatments 4 weeks apart
Page 24
HANDS-FREE BODY TREATMENT •Platform supports multiple technologies •Saves time for the operator •Allows increased treatment time and improved efficiency •Reproducible treatment protocol and results •Addresses multiple problems of the body InMode Proprietary Technology IV
Page 25
MULTIPLE SIMULTANEOUS TREATMENTS
Page 26
___________________________ Note: These are sample results and may not be indicative of actual results. Evolve: Dr. S. Theodorou & Dr. C. Chia “After” result reflects a series of treatments NON-INVASIVE BODY TREATMENT
Page 27
CUSTOMIZED FACIAL TREATMENT •The zoom effect, social media, and celebrity culture continue to drive patient demand for sculpted cheeks, chiseled jawlines, and more defined facial features. •Consumers want to avoid surgery in pursuit of more natural-looking results, making nonsurgical facial remodeling procedures the top treatments in their quest to achieve a more youthful appearance without anesthesia, surgical scars, or downtime. THE ULTIMATE ALL-IN-ONE FACIAL PLATFORM REDEFINING NON-INVASIVE FACIAL TREATMENTS InMode Proprietary Technology V
Page 28
FSN TREATMENT AND BLOCK HEATING
Page 29
___________________________ Note: These are sample results and may not be indicative of actual results. Evoke: Dr. R. Rohrich and D. Weir, NP-C Photo Courtesy: Dr. K. Donnay DEFINE + MORPHEUS8 PROCEDURE “After” result reflects a series of treatments
Page 30
OCULAR TREATMENTS ✓Health Canada certified to address the symptoms of dry eye disease (DED) caused by Meibomian Gland Dysfunction (MGD). ✓Intended for use in the periorbital area and eyelids and relieves inflammation of meibomian glands and eye irritation. ✓This groundbreaking, nonsurgical device delivers safe and highly efficacious precision treatments . InMode Proprietary Technology VI
Page 31
INMODE’S EXISTING PORTFOLIO OF TECHNOLOGIES Since 2010, InMode has launched multiple innovative product platforms
Page 32
HISTORICAL PERFORMANCE Revenue / Non-GAAP Net Income ($ in millions) Revenue Non-GAAP Net Income •High profitability; 78%-80% gross margins •InMode technologies have sustainable cost advantage •Outsourced manufacturing at fixed cost per unit •Long-term agreements with Medimor for major parts and sub-systems •Controls procurement of major components and quality assurance •Sustainable tax advantage •Facilities are in highest tax benefit zone within Israel •Starting from 2022, the Company’s corporate tax rate is expected to be approximately 7.5-10%. 0,0 125,0 250,0 375,0 500,0 2016 2018 2020 2022 2024 Q1 2023 Q3 2023 Q1 2024 Q3 2024 Q1 2025 Q3 2025
Page 33
INMODE QUALITY MEDICAL MANUFACTURING
Page 34
Podium Presentations | Clinical Trials | Publications |Training | Reference Calls | Media S. FARHANG L. CHEUcK M. PEREDO E. DAYAN S. ASTONR. ROHRICH A. GHAVAMI A. HOYOS S. NAZARIAN M. KARRAM KEY OPINION LEADERS & LUMINARIES
Page 35
“The mean skin surface area reduction was 25.8% in regions treated with radiofrequency plus SAL at 6 weeks, and increased to 36.4% at 1 year.” - Aesthetic Surgery Journal “RFAL with its safety features presents an alternative to SupL, which has a higher complication rate, risk for contour deformities, and steeper learning curve.” - PRS Global Open “The novel RFAL technology offers immediate skin tightening effect that is stable over time.” - JCDSA “This technology allows precise soft tissue modeling at multiple levels to enhance results over traditional suction- assisted lipecectomy.” - Aesthetic Plastic Surgery 100+ Peer Reviewed Publications and Counting LEADER IN CLINICAL EXCELLENCE
Page 36
CONSUMER AWARENESS – 2025 WRAPPED REPORT